國科微(300672.SZ)跌停 節前發佈業績預吿
格隆匯2月7日丨國科微(300672.SZ)盤中跌停,報價115.42元,股價跌至年線位置,為2021年10月以來新低,最新市值210億元。1月28日(春節前),國科微發佈業績預吿,預計2021年歸母淨利2.5億元-3億元,同比增長252.83%-323.40%。還值得注意的是,1月10日,國科微發佈股東減持計劃公吿,持有期超過三年的國家集成電路產業投資基金(國家大基金),計劃於當日起15個交易日後的6個月內,減持不超過364萬股,佔總股本的2%。國家大基金在國科微上市前就已位列股東之一,國科微上市後,國家大基金持有其1764.70萬股,佔發行後股本比例的15.79%,為第二大股東。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.